IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:IRMD
- CUSIP: N/A
- Web: www.iradimed.com
Capitalization:- Market Cap: $101.59 million
- Outstanding Shares: 10,582,000
Average Prices:- 50 Day Moving Avg: $9.94
- 200 Day Moving Avg: $8.89
- 52 Week Range: $7.85 - $18.00
P/E:- Trailing P/E Ratio: 39.96
- Foreward P/E Ratio: 86.82
- P/E Growth: 4.22
Sales & Book Value:- Annual Revenue: $24.35 million
- Price / Sales: 4.15
- Book Value: $2.96 per share
- Price / Book: 3.23
Profitability:- EBIDTA: $4.51 million
- Net Margins: 11.61%
- Return on Equity: 8.98%
- Return on Assets: 7.69%
Debt:- Current Ratio: 9.09%
- Quick Ratio: 7.91%
Misc:- Average Volume: 35,655 shs.
- Beta: 1.5
- Short Ratio: 32.32
Frequently Asked Questions for iRadimed Corporation (NASDAQ:IRMD)
What is iRadimed Corporation's stock symbol?
iRadimed Corporation trades on the NASDAQ under the ticker symbol "IRMD."
How will iRadimed Corporation's stock buyback program work?
iRadimed Corporation announced that its board has initiated a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $8,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.
How were iRadimed Corporation's earnings last quarter?
iRadimed Corporation (NASDAQ:IRMD) announced its earnings results on Friday, July, 28th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.01) by $0.07. The company earned $5.50 million during the quarter, compared to analyst estimates of $5.41 million. iRadimed Corporation had a return on equity of 8.98% and a net margin of 11.61%. The company's quarterly revenue was down 44.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.24 earnings per share. View iRadimed Corporation's Earnings History.
When will iRadimed Corporation make its next earnings announcement?
What guidance has iRadimed Corporation issued on next quarter's earnings?
iRadimed Corporation issued an update on its third quarter earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $0.02-0.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.03. The company issued revenue guidance of $5.5-5.6 million, compared to the consensus revenue estimate of $5.76 million.
Where is iRadimed Corporation's stock going? Where will iRadimed Corporation's stock price be in 2017?
1 brokerages have issued 12 month price objectives for iRadimed Corporation's stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate iRadimed Corporation's stock price to reach $12.00 in the next twelve months. View Analyst Ratings for iRadimed Corporation.
Who are some of iRadimed Corporation's key competitors?
Some companies that are related to iRadimed Corporation include MannKind Corporation (MNKD), Nymox Pharmaceutical Corporation (NYMX), Vital Therapies (VTL), Cascadian Therapeutics (CASC), Merrimack Pharmaceuticals (MACK), Biodel (ALBO), Verona Pharma PLC American Depositary Share (VRNA), Spring Bank Pharmaceuticals (SBPH), Signal Genetics (MGEN), vTv Therapeutics (VTVT), Aileron Therapeutics (ALRN), Advaxis (ADXS), Compugen (CGEN), Osiris Therapeutics (OSIR), Ocular Therapeutix (OCUL), Vascular Biogenics (VBLT), Verastem (VSTM) and Anavex Life Sciences Corp. (AVXL).
Who are iRadimed Corporation's key executives?
iRadimed Corporation's management team includes the folowing people:
- Roger Susi, Chairman of the Board, President, Chief Executive Officer, Founder
- Chris Scott, Chief Financial Officer, Secretary
- John McCreery, Chief Operating Officer
- Brent Johnson, Executive Vice President - Worldwide Sales and Marketing
- Fran Casey, Vice President - Regulatory and Quality Assurance
- Steve Nardi, Vice President - Manufacturing
- Louis Waldman, Controller
- Jonathan A. Kennedy, Director
- Anthony Vuoto, Director
- Monty K. Allen, Independent Director
Who owns iRadimed Corporation stock?
iRadimed Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ameriprise Financial Inc. (3.22%), Mondrian Investment Partners LTD (1.93%), Vanguard Group Inc. (1.69%), Granite Investment Partners LLC (1.05%), Menta Capital LLC (0.66%) and Spark Investment Management LLC (0.62%). Company insiders that own iRadimed Corporation stock include Brent Johnson, James B Hawkins, Monty K Allen, Roger E Susi, Serge Novovich and Steven M Nardi. View Institutional Ownership Trends for iRadimed Corporation.
Who sold iRadimed Corporation stock? Who is selling iRadimed Corporation stock?
iRadimed Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, OxFORD Asset Management LLP, Bank of New York Mellon Corp, Granite Investment Partners LLC and Spark Investment Management LLC. View Insider Buying and Selling for iRadimed Corporation.
Who bought iRadimed Corporation stock? Who is buying iRadimed Corporation stock?
iRadimed Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Citigroup Inc., Menta Capital LLC, Neuberger Berman Group LLC, Connors Investor Services Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for iRadimed Corporation.
How do I buy iRadimed Corporation stock?
Shares of iRadimed Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iRadimed Corporation's stock price today?
One share of iRadimed Corporation stock can currently be purchased for approximately $9.55.
MarketBeat Community Rating for iRadimed Corporation (NASDAQ IRMD)MarketBeat's community ratings are surveys of what our community members think about iRadimed Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for iRadimed Corporation (NASDAQ:IRMD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $12.00 (25.65% upside) |
Analysts' Ratings History for iRadimed Corporation (NASDAQ:IRMD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/31/2017 | Roth Capital | Upgrade | Neutral -> Buy | $9.00 -> $12.00 | Medium |  |
(Data available from 9/23/2015 forward)
Earnings History for iRadimed Corporation (NASDAQ:IRMD)Earnings History by Quarter for iRadimed Corporation (NASDAQ IRMD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/26/2017 | | $0.03 | | | | | N/A | |
| 7/28/2017 | Q2 2017 | ($0.01) | $0.06 | $5.41 million | $5.50 million | View | N/A | |
| 4/28/2017 | Q1 2017 | ($0.02) | ($0.02) | $5.26 million | $5.16 million | View | N/A | |
| 2/6/2017 | Q416 | $0.04 | $0.11 | $6.09 million | $6.00 million | View | Listen | |
| 10/28/2016 | Q316 | $0.09 | $0.14 | $7.50 million | $7.70 million | View | Listen | |
| 7/29/2016 | Q216 | $0.21 | $0.24 | $9.60 million | $9.90 million | View | Listen | |
| 4/29/2016 | Q1 | $0.18 | $0.21 | $9.05 million | $8.96 million | View | Listen | |
| 2/5/2016 | Q415 | $0.19 | $0.22 | $8.80 million | $8.80 million | View | N/A | |
| 10/30/2015 | Q315 | $0.16 | $0.19 | $7.70 million | $8.20 million | View | Listen | |
| 7/30/2015 | Q215 | $0.12 | $0.15 | $7.10 million | $7.60 million | View | Listen | |
| 4/30/2015 | Q115 | $0.10 | $0.12 | $6.90 million | $7.00 million | View | N/A | |
| 2/5/2015 | Q4 | ($0.01) | $0.02 | $3.50 million | $3.58 million | View | N/A | |
| 10/30/2014 | Q3 | $0.01 | $0.02 | $3.80 million | $3.80 million | View | N/A | |
| 8/12/2014 | Q214 | | $0.11 | $2.80 million | $4.70 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for iRadimed Corporation (NASDAQ:IRMD)2017 EPS Consensus Estimate: $0.08
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.02) | ($0.02) | ($0.02) |
| Q2 2017 | 1 | $0.00 | $0.00 | $0.00 |
| Q3 2017 | 1 | $0.03 | $0.03 | $0.03 |
| Q4 2017 | 1 | $0.07 | $0.07 | $0.07 |
(Data provided by Zacks Investment Research)
Dividend History for iRadimed Corporation (NASDAQ:IRMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for iRadimed Corporation (NASDAQ:IRMD)Insider Ownership Percentage: 60.10%
Institutional Ownership Percentage: 14.19%
Insider Trades by Quarter for iRadimed Corporation (NASDAQ:IRMD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/1/2017 | Steven M Nardi | VP | Sell | 4,634 | $8.32 | $38,554.88 | |
| 2/9/2017 | Roger E Susi | CEO | Buy | 10,000 | $8.60 | $86,000.00 | |
| 11/29/2016 | Roger E Susi | CEO | Buy | 5,000 | $11.24 | $56,200.00 | |
| 11/15/2016 | Roger E Susi | CEO | Buy | 5,000 | $10.46 | $52,300.00 | |
| 8/16/2016 | Steven M Nardi | VP | Sell | 2,096 | $17.11 | $35,862.56 | |
| 6/14/2016 | Monty K. Allen | Director | Sell | 2,275 | $20.00 | $45,500.00 | |
| 6/13/2016 | Monty K Allen | Director | Sell | 2,100 | $20.44 | $42,924.00 | |
| 2/19/2016 | Serge Novovich | Director | Sell | 2,910 | $17.23 | $50,139.30 | |
| 2/18/2016 | Steven M Nardi | VP | Sell | 192 | $17.00 | $3,264.00 | |
| 12/23/2015 | Roger E Susi | CEO | Sell | 156,521 | $23.28 | $3,643,808.88 | |
| 12/18/2015 | Roger E Susi | CEO | Sell | 1,043,479 | $23.28 | $24,292,191.12 | |
| 12/16/2015 | Steven M. Nardi | VP | Sell | 4,438 | $26.80 | $118,938.40 | |
| 12/8/2015 | Brent Johnson | VP | Sell | 22,659 | $30.92 | $700,616.28 | |
| 12/7/2015 | Steven M. Nardi | VP | Sell | 624 | $31.02 | $19,356.48 | |
| 12/4/2015 | Brent Johnson | VP | Sell | 400 | $31.51 | $12,604.00 | |
| 12/3/2015 | Brent Johnson | VP | Sell | 26,880 | $31.52 | $847,257.60 | |
| 12/1/2015 | Serge Novovich | Director | Sell | 1,000 | $31.12 | $31,120.00 | |
| 11/25/2015 | James B. Hawkins | Director | Sell | 5,290 | $30.98 | $163,884.20 | |
| 8/25/2015 | Monty K. Allen | Director | Sell | 6,250 | $24.85 | $155,312.50 | |
| 12/29/2014 | Steven M Nardi | VP | Buy | 2,100 | $12.58 | $26,418.00 | |
| 7/21/2014 | James B Hawkins | Director | Buy | 80,000 | $6.25 | $500,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for iRadimed Corporation (NASDAQ:IRMD)
Latest Headlines for iRadimed Corporation (NASDAQ:IRMD)
| Source: |
|
| Date | Headline |
|---|
 | IRADIMED CORPORATION to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 7:26 PM |
 | Entellus Medical (ENTL) and iRadimed Corporation (NASDAQ:IRMD) Critical Comparison
www.americanbankingnews.com - August 7 at 4:28 PM |
| Zacks Investment Research Upgrades iRadimed Corporation (IRMD) to Buy
www.americanbankingnews.com - August 5 at 12:40 AM |
| Reviewing Entellus Medical (ENTL) & iRadimed Corporation (NASDAQ:IRMD)
www.americanbankingnews.com - August 5 at 12:12 AM |
| iRadimed Corporation (IRMD) versus Penumbra (PEN) Head to Head Analysis
www.americanbankingnews.com - August 4 at 10:16 PM |
| Corporate News Blog - Cesca Therapeutics Announces Issuance of New Cellular Processing Patent
finance.yahoo.com - July 31 at 7:23 PM |
| Analysts Anticipate iRadimed Corporation (NASDAQ:IRMD) to Post $0.00 EPS
www.americanbankingnews.com - July 31 at 2:34 PM |
| iRadimed Corporation (NASDAQ:IRMD) Upgraded to Buy by Roth Capital
www.americanbankingnews.com - July 31 at 9:09 AM |
| IRADIMED CORPORATION Announces Second Quarter 2017 Financial Results
finance.yahoo.com - July 28 at 11:34 PM |
| Edited Transcript of IRMD earnings conference call or presentation 28-Jul-17 3:00pm GMT
finance.yahoo.com - July 28 at 11:34 PM |
| iRadimed Corporation (IRMD) Announces Earnings Results
www.americanbankingnews.com - July 28 at 10:30 PM |
| Analysts Anticipate iRadimed Corporation (NASDAQ:IRMD) to Announce ($0.01) Earnings Per Share
www.americanbankingnews.com - July 28 at 8:44 PM |
| iRadimed Corporation (IRMD) Updates Q3 Earnings Guidance
www.americanbankingnews.com - July 28 at 9:46 AM |
| iRadimed Corporation (IRMD) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - July 27 at 12:39 PM |
 | iRadimed Corp. (IRMD)
seekingalpha.com - July 23 at 3:15 AM |
| Critical Review: iRadimed Corporation (IRMD) & Masimo Corporation (MASI)
www.americanbankingnews.com - July 18 at 12:27 AM |
| Financial Contrast: Entellus Medical (ENTL) and iRadimed Corporation (NASDAQ:IRMD)
www.americanbankingnews.com - July 16 at 4:24 PM |
| Head-To-Head Analysis: iRadimed Corporation (NASDAQ:IRMD) and Tactile Systems Technology (TCMD)
www.americanbankingnews.com - July 15 at 2:18 PM |
| Critical Survey: Iradimed Corp (IRMD) and Entellus Medical (ENTL)
www.americanbankingnews.com - July 10 at 12:20 PM |
| Reviewing iRadimed Corporation (IRMD) & Penumbra (PEN)
www.americanbankingnews.com - July 7 at 10:20 PM |
| iRadimed Corporation (NASDAQ:IRMD) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 2 at 11:28 AM |
| iRadimed Corporation (IRMD) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - June 27 at 3:28 PM |
| IRadimed Corp.: Gathering momentum, can it sustain its performance?
finance.yahoo.com - June 26 at 7:48 PM |
| Zacks: iRadimed Corporation (IRMD) Given $10.00 Average Price Target by Brokerages
www.americanbankingnews.com - June 26 at 4:32 PM |
| iRadimed Corporation (IRMD) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - June 24 at 10:22 PM |
| ETFs with exposure to IRadimed Corp. : June 5, 2017
finance.yahoo.com - June 5 at 6:00 PM |
| Iradimed Corp (IRMD) to Repurchase $8.00 million in Stock
www.americanbankingnews.com - June 4 at 11:28 AM |
| Iradimed Corp (IRMD) VP Steven M. Nardi Sells 4,634 Shares
www.americanbankingnews.com - June 1 at 8:32 PM |
| ETFs with exposure to IRadimed Corp. : May 22, 2017
finance.yahoo.com - May 22 at 5:27 PM |
| ETFs with exposure to IRadimed Corp. : May 9, 2017
finance.yahoo.com - May 9 at 5:45 PM |
| IRadimed Corp. :IRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
finance.yahoo.com - May 8 at 5:37 PM |
| Somewhat Negative Media Coverage Likely to Impact Iradimed Corp (IRMD) Share Price
www.americanbankingnews.com - May 2 at 9:38 PM |
| Iradimed Corp (IRMD) Earns Daily News Impact Score of 0.04
www.americanbankingnews.com - April 29 at 11:59 PM |
| Edited Transcript of IRMD earnings conference call or presentation 28-Apr-17 3:00pm GMT
finance.yahoo.com - April 29 at 9:08 AM |
| Iradimed Corp (IRMD) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - April 29 at 1:27 AM |
| Iradimed Corp (IRMD) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - April 29 at 1:22 AM |
| ETFs with exposure to IRadimed Corp. : April 28, 2017
finance.yahoo.com - April 28 at 6:57 PM |
| Iradimed Corp (IRMD) Issues FY17 Earnings Guidance
www.americanbankingnews.com - April 28 at 10:21 AM |
| Iradimed Corp (IRMD) Updates Q2 Earnings Guidance
www.americanbankingnews.com - April 28 at 10:20 AM |
| IRADIMED CORPORATION Announces First Quarter 2017 Financial Result
finance.yahoo.com - April 28 at 9:55 AM |
| IRadimed reports 1Q loss
finance.yahoo.com - April 28 at 9:55 AM |
| Investor Network: iRadimed Corp to Host Earnings Call
finance.yahoo.com - April 28 at 9:55 AM |
| Iradimed Corp (IRMD) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 10:13 PM |
| IRADIMED CORPORATION to Hold 2017 First Quarter Financial Results Conference Call on April 28th
finance.yahoo.com - April 20 at 11:23 AM |
| Iradimed Corp (IRMD) Given Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 18 at 6:51 PM |
| Iradimed Corp (IRMD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 9 at 11:51 AM |
| ETFs with exposure to IRadimed Corp. : April 7, 2017
finance.yahoo.com - April 7 at 5:50 PM |
| Iradimed Corp (IRMD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 3 at 11:37 PM |
 | Iradimed Corp. (IRMD) Names John McCreery as COO
www.streetinsider.com - March 30 at 11:20 PM |
| IRADIMED Names John McCreery Chief Operating Officer
finance.yahoo.com - March 30 at 6:20 PM |
iRadimed Corporation (IRMD) Chart for Saturday, September, 23, 2017
